---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-018634"
form_type: "8-K"
ticker: "TELO"
cik: "0001971532"
company_name: "Telomir Pharmaceuticals, Inc."
filed_at: "2025-10-20T23:59:59+00:00"
generated_at: "2026-05-17T03:18:26.275058+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Telomir signs binding LOI to acquire TELI, consolidating worldwide rights to Telomir-1

## Summary
- Acquires all TELI shares via stock-for-stock exchange; exchange ratio based on third-party valuation.
- Certain TELI shareholders to contribute $5M cash: $1M at closing, $2M on FDA IND acceptance, $2M on Phase 1/2 start.
- Transaction consolidates global IP rights to Telomir-1, an oral epigenetic therapy for cancer and aging.
- No TELI leadership retained post-closing; TELI shareholders subject to six-month lock-up.
- Closing subject to due diligence, board/stockholder approvals, regulatory clearances within 90 days.

## SEC filing metadata
- accession: 0001493152-25-018634
- form_type: 8-K
- ticker: TELO
- cik: 0001971532
- company_name: Telomir Pharmaceuticals, Inc.
- filed_at: 2025-10-20T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1971532/000149315225018634/0001493152-25-018634-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1971532/000149315225018634/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-018634
- JSON: https://secwatch.observer/filing/0001493152-25-018634.json
- Plain text: https://secwatch.observer/filing/0001493152-25-018634.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.